Results 141 to 150 of about 110,938 (270)

Re chronic stable angina guidelines

Indian Heart Journal, 2017
Prabha Nini Gupta, Praveen Velappan, Krishna Kumar Bhaskara Pillai, Riyas Abdul Salam   +3 more
doaj   +1 more source

Elevated ASGR1 as a Potential Diagnostic Biomarker for Coronary Artery Disease and Predictor of Adverse Outcomes in Hypertensive Patients

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Asialoglycoprotein receptor 1 (ASGR1) is linked to lipid metabolism and CAD, but its role in hypertensive CAD patients is unclear. This single‐center study included 345 hypertensive patients (59 non‐CAD, 286 CAD). Plasma ASGR1 was higher in CAD patients, correlated with multiple markers and HDL‐C, had high diagnostic value (better than traditional ...
Ying Liu, Xinyu Zhou, Peng Hao, Ying Guo, Ning Wang, Kuibao Li, Hongjie Chi, Hong Li, Xiaoyan Yang, Jing Li, Jiuchang Zhong, Lin Zhao, Ying Dong   +12 more
wiley   +1 more source

Dynamics of proinflammatory cytokines level in stable angina (II–III functional class)

Сеченовский вестник, 2016
The article discusses the evaluation of cytokine level (IL-1β, IL-6) in patients with II–III functional class stable angina. In the group of patients with II–III class stable angina, the standard therapy failed to normalize the level of proinflammatory ...
E. K. Gordeeva, A. H. Kade, S. A. Zanin
doaj  

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

American Journal of Hematology, Volume 101, Issue 5, Page 939-948, May 2026.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth, Christopher J. Patriquin, Jeff Szer, Louis Terriou, Ami S. Patel, Jesse Metzger, Philippe Gustovic, Jun‐ichi Nishimura, Robert A. Brodsky   +8 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1287-1308, May 2026.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. [PDF]

, 2019
Background: Evaluating women with symptoms suggestive of coronary artery disease (CAD) remains challenging. A blood-based precision medicine test yielding an age/sex/gene expression score (ASGES) has shown clinical validity in the diagnosis of ...
Budoff, Matthew J, Gul, Burcu, Herman, Lee, Huang, Lin, Kuo, Jane Z, Ladapo, Joseph A, Lansky, Alexandra, Maniet, Bruce, Monane, Mark, Sharp, David   +9 more
core   +1 more source

Two Cases of Kounis Syndrome Caused by Contrast Medium: Early Extracorporeal Membrane Oxygenation

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In cardiology, Kounis syndrome (KS), also known as allergic angina or myocardial infarction, is often overlooked in emergencies. Its pathophysiology differs from that of allergic reactions such as anaphylaxis, making differentiation essential.
Kiichi Yano, Yu Asami, Takumi Inoue, Emiko Takego, Kenji Tamai, Hiroyuki Takahashi   +5 more
wiley   +1 more source

Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study

Cardiology and Therapy
Introduction The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice ...
Luís Henrique Wolff Gowdak, Paulo Magno Martins Dourado, Dalton Bertolim Précoma, César de Oliviera Lopes Dusilek, Francisco Maia da Silva, Juan Carlos Yugar-Toledo, Felipe Montes Pena, Domingos Antônio de Almeida Gomes, Elizabeth do Espírito Santo Cestário, Olavo Raimundo Guimarães, Conrado Roberto Hoffmann Filho, Carlos Filinto de Almeida, Flávio de Souza Brito, Gerez Fernandes Martins, Victor Rodrigues Ribeiro Ferreira, Marcella Chaves Flores, Mayara Lídia da Silva, on behalf of the V-GOOD Investigators   +17 more
doaj   +1 more source

Batch Size Effects on Mid‐2025 State‐of‐the‐Art Large Language Model Performance in Automated Title and Abstract Screening

Cochrane Evidence Synthesis and Methods, Volume 4, Issue 3, May 2026.
ABSTRACT Background Manual abstract screening is a primary bottleneck in evidence synthesis. Emerging evidence suggests that large language models (LLMs) can automate this task, but their performance when processing multiple references simultaneously in “batches” is uncertain.
Petter Fagerberg, Oscar Sallander, Kim Vikhe Patil, Anders Berg, Anastasia Nyman, Natalia Borg, Thomas Lindén   +6 more
wiley   +1 more source

CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT

Российский кардиологический журнал, 2009
Aim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years).
N. A. Shostak, O. G. Smolenskaya, A. V. Panov, A. A. Klimenko, D. Yu. Andriyashkina, N. A. Tverdova   +5 more
doaj